Krka Out Of The Blocks Solidly In Q1, With Russia Still Largest Market
Slovenian Firm ‘Second Largest Foreign Provider Of Generic Medicines’ In Russia
Executive Summary
Krka has reaffirmed its full-year financial goals after a solid start to 2024, which included 8% revenue growth for its pharmaceutical products. Generics Bulletin examines the company’s sprawling global operations.